ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

CSL and Eli Lilly side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

CSLEli Lilly
studies on the registry2682,262
open to participants now18173
phase 3 studies under way6104
reach primary completion within a year4104
programswith a study of their own in two years1193+3 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseCSLEli Lilly
Phase 100%

Eli Lilly: 42 of its 93 programs at phase 1

  1. LY4256984phase 1
  2. LY3981314phase 1
  3. LY4167586phase 1
  4. LY4405094phase 1
  5. LY3873862phase 1

and 37 more — sign in to see them all

45%
Phase 2

CSL: 3 of its 11 programs at phase 2

  1. VIT-2763phase 2
  2. anumigilimabphase 2
  3. hemopexin (human)phase 2
27%

Eli Lilly: 28 of its 93 programs at phase 2

  1. macupatidephase 2
  2. LY4065967phase 2
  3. zotemtegrastphase 2
  4. LY4515100phase 2
  5. LY4005130phase 2

and 23 more — sign in to see them all

30%
Phase 3

CSL: 4 of its 11 programs at phase 3

  1. CSL300phase 3
  2. Immunoglobulins, Intravenousphase 3
  3. Four-factor Prothrombin Complex Concentratephase 3
  4. lonoctocog alfaphase 3
36%

Eli Lilly: 13 of its 93 programs at phase 3

  1. orforglipronphase 3
  2. eloralintidephase 3
  3. brenipatidephase 3
  4. retatrutidephase 3
  5. Imlunestrantphase 3

and 8 more — sign in to see them all

14%
Approved, new studies

CSL: 4 of its 11 programs at approved, new studies

  1. Immunoglobulinsapproved, new study
  2. Hizentraapproved, new study
  3. alpha 1-Antitrypsinapproved, new study
  4. garadacimabapproved, new study
36%

Eli Lilly: 10 of its 93 programs at approved, new studies

  1. Tirzepatideapproved, new study
  2. abemaciclibapproved, new study
  3. pirtobrutinibapproved, new study
  4. selpercatinibapproved, new study
  5. donanemabapproved, new study

and 5 more — sign in to see them all

11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
CSL3 readouts · 1 phase 3·····

CSL, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Four-factor Prothrombin Complex Concentratephase 3 · Apr 6 · NCT07094087
···

CSL, Aug ’27: 1 program whose next study reaches primary completion

  1. CSL300phase 3 · Aug 30 · NCT07619820
·

CSL, Oct ’27: 1 program whose next study reaches primary completion

  1. hemopexin (human)phase 2 · Oct 22 · NCT06699849
Eli Lilly49 readouts · 5 phase 3

Eli Lilly, Nov ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. abemaciclibapproved, new study · Nov 0 · NCT07818967
  2. BPL-003phase 2 · Nov 0 · NCT05660642
  3. brenipatidephase 3 · Nov 0 · NCT06606106
  4. LY3938577phase 2 · Nov 0 · NCT07215312
  5. LY4515100phase 2 · Nov 0 · NCT07511816

and 2 more — sign in to see them all

Eli Lilly, Dec ’26: 5 programs whose next study reaches primary completion

  1. eloralintidephase 3 · Dec 0 · NCT07738614
  2. GIPR Agonist LY3537021phase 2 · Dec 0 · NCT07169851
  3. LY4167586phase 1 · Dec 0 · NCT07225556
  4. ORN252phase 1 · Dec 0 · NCT07439796
  5. ORX750phase 2 · Dec 0 · NCT06752668

Eli Lilly, Jan ’27: 2 programs whose next study reaches primary completion

  1. LY4355756phase 1 · Jan 0 · NCT07765498
  2. parunoflastphase 2 · Jan 0 · NCT07867340

Eli Lilly, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3981314phase 1 · Feb 0 · NCT07005284
  2. mirikizumabapproved, new study · Feb 0 · NCT07446101
  3. orforglipronphase 3 · Feb 0 · NCT06672549

Eli Lilly, Mar ’27: 3 programs whose next study reaches primary completion

  1. lepodisiranphase 3 · Mar 0 · NCT07914738
  2. macupatidephase 2 · Mar 0 · NCT07215559
  3. solbinsiranphase 2 · Mar 0 · NCT07269210

Eli Lilly, Apr ’27: 3 programs whose next study reaches primary completion

  1. Anti-BAFF-R/Anti-CD3 Bispecific Antibody LY4152199phase 1 · Apr 0 · NCT07101328
  2. LY4065967phase 2 · Apr 0 · NCT05986292
  3. olomorasibphase 3 · Apr 0 · NCT04956640

Eli Lilly, May ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. clazakizumabphase 2 · May 0 · NCT07783802
  2. lebrikizumabapproved, new study · May 0 · NCT06338995
  3. LY4005130phase 2 · May 0 · NCT07533019
  4. nisotirostidephase 2 · May 0 · NCT06897475
  5. zotemtegrastphase 2 · May 0 · NCT07186101

Eli Lilly, Jun ’27: 4 programs whose next study reaches primary completion

  1. LY3839056 IVphase 1 · Jun 0 · NCT07945314
  2. LY4395089phase 2 · Jun 0 · NCT07483099
  3. vepugratinibphase 3 · Jun 0 · NCT05614739
  4. ORX489phase 1 · Jun 30 · NCT07413666

Eli Lilly, Jul ’27: 2 programs whose next study reaches primary completion

  1. LY4057996phase 1 · Jul 0 · NCT06945406
  2. LY4226695phase 1 · Jul 0 · NCT07767487

Eli Lilly, Aug ’27: 7 programs whose next study reaches primary completion

  1. Imlunestrantphase 3 · Aug 0 · NCT07918859
  2. LY3439539phase 1 · Aug 0 · NCT07598370
  3. LY4088044phase 1 · Aug 0 · NCT07090785
  4. LY4256984phase 1 · Aug 0 · NCT07100119
  5. LY4302814phase 1 · Aug 0 · NCT07566338

and 2 more — sign in to see them all

Eli Lilly, Sep ’27: 6 programs whose next study reaches primary completion, 1 in phase 3

  1. LY3945262phase 1 · Sep 0 · NCT07943091
  2. LY4066708phase 1 · Sep 0 · NCT07046559
  3. LY4329090phase 1 · Sep 0 · NCT07808073
  4. mazdutidephase 2 · Sep 0 · NCT06143956
  5. naperiglipronphase 2 · Sep 0 · NCT06143956

and 1 more — sign in to see them all

Eli Lilly, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. abdenoflastphase 2 · Oct 0 · NCT06836232
  2. pirtobrutinibapproved, new study · Oct 0 · NCT05254743
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

CSL

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Eli Lilly

New programs 9

Reached a new phase 2

Study stopped 0

None

Primary completion later 9

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionCSLEli Lilly
Diabetes Mellitus, Type 1both · compare here

CSL in Diabetes Mellitus, Type 1: 1 program

  1. alpha 1-Antitrypsinapproved, new study

Their studies: CSL’s studies of Diabetes Mellitus, Type 1 in search

Eli Lilly in Diabetes Mellitus, Type 1: 4 programs

  1. macupatidephase 2
  2. LY3938577phase 2
  3. LY4057996phase 1
  4. Tirzepatideapproved, new study

Their studies: Eli Lilly’s studies of Diabetes Mellitus, Type 1 in search

Purpura, Thrombocytopenic, Idiopathicboth · compare here

CSL in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. Immunoglobulins, Intravenousphase 3
  2. Immunoglobulinsapproved, new study

Their studies: CSL’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Eli Lilly in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. pirtobrutinibapproved, new study

Their studies: Eli Lilly’s studies of Purpura, Thrombocytopenic, Idiopathic in search

COVID-19both · compare here

CSL in COVID-19: 1 program

  1. anumigilimabphase 2

Their studies: CSL’s studies of COVID-19 in search

Eli Lilly in COVID-19: 1 program

  1. baricitinibapproved, new study

Their studies: Eli Lilly’s studies of COVID-19 in search

Idiopathic Pulmonary Fibrosisboth · compare here

CSL in Idiopathic Pulmonary Fibrosis: 1 program

  1. garadacimabapproved, new study

Their studies: CSL’s studies of Idiopathic Pulmonary Fibrosis in search

Eli Lilly in Idiopathic Pulmonary Fibrosis: 1 program

  1. idelalisibapproved, new study

Their studies: Eli Lilly’s studies of Idiopathic Pulmonary Fibrosis in search

Kidney Failure, Chronicboth · compare here

CSL in Kidney Failure, Chronic: 1 program

  1. CSL300phase 3

Their studies: CSL’s studies of Kidney Failure, Chronic in search

Eli Lilly in Kidney Failure, Chronic: 1 program

  1. eloralintidephase 3

Their studies: Eli Lilly’s studies of Kidney Failure, Chronic in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

CSL in Pulmonary Disease, Chronic Obstructive: 1 program

  1. alpha 1-Antitrypsinapproved, new study

Their studies: CSL’s studies of Pulmonary Disease, Chronic Obstructive in search

Eli Lilly in Pulmonary Disease, Chronic Obstructive: 1 program

  1. lebrikizumabapproved, new study

Their studies: Eli Lilly’s studies of Pulmonary Disease, Chronic Obstructive in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: CSL 3 of 11 · Eli Lilly 50 of 93 programs (25 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Eli Lilly: 3).